Kostic M. (Co-investigator): A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients with Neurofibromatosis Type 1 (NF1) – Associated Inoperabl…

Kostic M. (Co-investigator): A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients with Neurofibromatosis Type 1 (NF1) – Associated Inoperable Plexiform Neurofibromas (PNs) that are Causing Significant Morbidity, 19-1051 PI: Timothy Gershon to Sponsor: SpringWorks Therapeutics Operating Company, PBC. (Active).